Sabbin bayanai akan asma mai tsanani

A KYAUTA Kyauta 3 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Amgen a yau ya ba da sanarwar sakamako daga ƙididdigar bayan-hoc mai mahimmanci na NAVIGATOR Phase 3 da gwaji na PATHWAY Phase 2b sun nuna TEZSPIRE ™ (tezepelumab-ekko) ya nuna raguwa a cikin ƙimar haɓakar asma na shekara-shekara (AAER) a tsakanin ƙungiyoyin marasa lafiya masu fama da asma. 1 Wadannan binciken sun goyi bayan rawar TEZSPIRE a matsayin magani na farko ga yawancin mutanen da ke fama da asma mai tsanani, ba tare da la'akari da matakan biomarker ba.1           

A cikin binciken da aka tattara, TEZSPIRE, lokacin da aka ƙara zuwa daidaitattun kulawa (SoC), rage yawan haɓakar asma a cikin marasa lafiya, ba tare da la'akari da ƙididdigar eosinophil na jini ba, yana nuna ingantaccen inganci tare da 71% (≥300 Kwayoyin da microliter), 48% (<300) Kwayoyin da microliter) da 48% (<150 Kwayoyin da microliter) raguwa a cikin AAER a kan 52 makonni, idan aka kwatanta da placebo da aka kara zuwa SoC.1 A cikin wannan bincike, TEZSPIRE kuma ya nuna ingantawa a cikin AAER a cikin marasa lafiya ba tare da la'akari da ƙananan exhaled nitric oxide ba. FeNO) matakin da yanayin rashin lafiyar sama da makonni 52, idan aka kwatanta da placebo.1

Bugu da ƙari, a cikin binciken bincike da aka riga aka yi daga NAVIGATOR, TEZSPIRE ya nuna ingantaccen inganci a cikin shekara ba tare da la'akari da yanayi ba.2 Bayanai sun nuna cewa TEZSPIRE ya rage AAER da 63% (hunturu), 46% (spring), 62% (rani) da kuma 54% (kaka) idan aka kwatanta da placebo.2 Adadin marasa lafiya tare da haɓaka ya kasance ƙasa a cikin ƙungiyar TEZSPIRE fiye da rukunin placebo a duk yanayi.2

“Yawancin masu fama da cutar asma suna da nau'ikan kumburi da yawa, waɗanda ke haifar da allergens, cututtukan ƙwayoyin cuta da ƙwayoyin cuta, da gurɓataccen iska, waɗanda duk suna iya ba da gudummawa ga ci gaba da ɓarna. Wadannan sababbin sakamakon suna nuna yiwuwar TEZSPIRE don rage yawan ciwon fuka mai tsanani a cikin marasa lafiya ba tare da la'akari da matakan biomarker da abubuwan da ke haifar da yanayi ba, "in ji Dokta Jonathan Corren, mamba na asibiti a David Geffen School of Medicine, UCLA, da kuma babban mai bincike na gwaji na PATHWAY.

"Mun yi farin ciki da ci gaba da ganin marasa lafiya suna fuskantar ƙarancin hare-haren fuka biyo bayan jiyya tare da TEZSPIRE bisa sakamakon sabon bincike a cikin NAVIGATOR da gwaji na PATHWAY," in ji David M. Reese, MD, mataimakin shugaban zartarwa na Bincike da Ci gaba a Amgen. "Wadannan sakamakon sun ƙara ƙarfafa imaninmu cewa TEZSPIRE na da yuwuwar zama magani mai canza canji ga mutanen da ke fama da asma ba tare da la'akari da yanayi ko takamaiman nau'in cutar asma ba."

Ana gabatar da waɗannan sakamakon a Cibiyar Nazarin Allergy, Asthma & Immunology (AAAAI) na Shekara-shekara na 2022.

An amince da TEZSPIRE a Amurka don maganin cutar asma mai tsanani kuma yana ƙarƙashin bita na tsari a cikin EU, Japan da wasu ƙasashe da dama a duniya.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...